A prominent pharma industry group has raised alarm over a Super Bowl advertisement from the digital healthcare firm Hims & Hers, which promotes an off-brand version of the diabetes medication Ozempic. The organization labels the ad as 'dangerous,' urging the U.S. Food and Drug Administration (FDA) to consider its potential impact on public health. This call to action highlights ongoing tensions between innovative healthcare solutions and established pharmaceutical companies, especially as Ozempic, which had sales of over $4.5 billion in 2022, becomes increasingly popular. As the ad campaign unfolds, viewers are encouraged to consider the implications of such marketing strategies on personal health and safety.